Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dor, J.
Right arrow Articles by Mashiach, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dor, J.
Right arrow Articles by Mashiach, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 10, No. 1, pp. 40-43, 1995
© 1995 European Society of Human Reproduction and Embryology

Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: a prospective randomized placebo-controlled double-blind study

J. Dor1, D.S. Seidman, E. Amudai, D. Bider, D. Levran and S. Mashiach

Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University Israel

Correspondence: 1To whom correspondence should be addressed

The objective of the study was to assess the effect of growth hormone (GH) supplementation to a combined gonado-trophin-releasing hormone agonist/human menopausal gonadotrophin (GnRHa/HMG) treatment protocol on ovarian response in ‘poor responders’ undergoing in-vitro fertilization (IVF). GH or a placebo were administered in a prospective randomized double-blind manner. A total of 14 poor-responder patients (oestradiol < 500 pg/ml, less than three oocytes retrieved in two previous IVF cycles) were randomly allocated to a combined treatment of either GnRHa/HMG/ GH (18 IU on alternate days, total dose 72 IU) or GnRHa/ HMG placebo. No difference was found between the study and control groups in the number of HMG ampoules used, the number of follicles (>14 mm) and serum oestradiol concentrations on the day of administration of human chorionic gonadotrophin (HCG), the number of oocytes retrieved and fertilized, and the number of embryos transferred. The GH group (n = 7) did not show a better ovulatory response in the study cycles; mean ± SD serum oestradiol on day of HCG 411 ± 124 versus 493 ± 291 pg/ml, aspirated oocytes 2.2 ± 1.5 versus 1.9 ± 2.0. Interestingly, when the above results for the placebo group were compared with their previous cycles (serum oestradiol 403 ± 231 pg/ml; 0.4 ± 0.5 aspirated oocytes), a non-specific effect was found. Follicular recruitment, oestradiol secretion by mature follicles and the number of oocytes retrieved in poor responders were not improved by GH supplementation.

Key words: follicular fluid/gonadotrophins/IGF-I/ovulation induction

Submitted on May 20, 1994; accepted on September 19, 1994.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
E.M. Kolibianakis, C.A. Venetis, K. Diedrich, B.C. Tarlatzis, and G. Griesinger
Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis
Hum. Reprod. Update, November 1, 2009; 15(6): 613 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
T.A. Gelbaya, M. Kyrgiou, T.C. Li, C. Stern, and L.G. Nardo
Low-dose aspirin for in vitro fertilization: a systematic review and meta-analysis
Hum. Reprod. Update, July 1, 2007; 13(4): 357 - 364.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L.-P. Cheung, P.-M. Lam, I. H. Lok, T. T.-Y. Chiu, S.-Y. Yeung, C.-C. Tjer, and C. J. Haines
GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial
Hum. Reprod., March 1, 2005; 20(3): 616 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
M. F. M. Mitwally and R. F. Casper
Aromatase Inhibition Reduces the Dose of Gonadotropin Required for Controlled Ovarian Hyperstimulation
Reproductive Sciences, September 1, 2004; 11(6): 406 - 415.
[Abstract] [PDF]

Home page
 Hum ReprodHome page
G. De Placido, C. Alviggi, A. Mollo, I. Strina, M.T. Varricchio, and M. Molis
Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone
Hum. Reprod., January 1, 2000; 15(1): 17 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice
The Insulin-Related Ovarian Regulatory System in Health and Disease
Endocr. Rev., August 1, 1999; 20(4): 535 - 582.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
V. Karande and N. Gleicher
A rational approach to the management of low responders in in-vitro fertilization: Opinion
Hum. Reprod., July 1, 1999; 14(7): 1744 - 1748.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Rabinovici, N. A. Cataldo, P. Dandekar, S. M. Rosenthal, S. E. Gargosky, N. Gesundheit, and M. C. Martin
Adjunctive Growth Hormone during Ovarian Hyperstimulation Increases Levels of Insulin-Like Growth Factor Binding Proteins in Follicular Fluid: A Randomized, Placebo-Controlled, Cross-Over Study
J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1171 - 1176.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.